Ethyl bromoacetate → 3-Hydroxy-5-phenoxypentanoic acid
反応式
[O:1]([CH2:8][CH2:9][CH:10]=[O:11])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.Br[CH2:13][C:14]([O:16]CC)=[O:15]>>[OH:11][CH:10]([CH2:9][CH2:8][O:1][C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1)[CH2:13][C:14]([OH:16])=[O:15]参加物
実験手順
Hollow magnetic microcapsules 31 were obtained under the same conditions as in Example 98 except that the purified enzyme solution (1) used in Example 98 was replaced by the crude enzyme solution (3) originated from a P91 strain and (R)-3-hydroxybutyryl CoA was replaced by (R,S)-3-hydroxy-5-phenoxyvaleryl CoA (prepared by hydrolyzing 3-hydroxy-5-phenoxy valerate obtained through a Reformatsky reaction with zinc using 3-phenoxypropanal and ethyl bromoacetate as raw materials, which were synthesized according to a procedure described in J. Org. Chem., 55, 1490-1492, 1990, to produce 3-hydroxy-5-phenoxy valeric acid and then following a procedure described in Eur. J. Biochem., 250, 432-439, 1997). An ultrasonic contrast agent employing the hollow magnetic microcapsules 31 is referred to as an ultrasonic contrast agent 31.
後処理
- customwere synthesized
出典と根拠
- ORDレコード
- ord-f48370d921354f6682895ba93763b010
- 出典データセット
- uspto-grants-2009_05
- 特許番号
- US07527809B2
反応ノート
読み込み中…